UBS downgrades Syngene to ‘sell’ on weak outlook, shares slip 3% on January 16, 2024 at 6:31 am

The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS.

Leave a comment

Your email address will not be published. Required fields are marked *